Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin αV

References

• Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr. 2011;15:105–115.
   PubMed Web of Science ®Google Scholar
• Lima ZS, Ghadamzadeh M, Arashloo FT, et al. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol. 2019;12:38.
   PubMed Web of Science ®Google Scholar
• Huang S, Murphy L, Xu W. Genes and functions from breast cancer signatures. BMC Cancer. 2018;18:473.
   PubMedGoogle Scholar
• Minchin RF, Butcher NJ. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance. BMC Genomics. 2018;19:513.
   PubMed Web of Science ®Google Scholar
• Carlisle SM, Trainor PJ, Doll MA, et al. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity. Mol Carcinog. 2018;57:1458–1466.
   PubMed Web of Science ®Google Scholar
• Stepp MW, Doll MA, Carlisle SM, et al. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231. Mol Carcinog. 2018;57:549–558.
   PubMed Web of Science ®Google Scholar
• Tiang JM, Butcher NJ, Cullinane C, et al. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One. 2011;6:e17031.
   PubMed Web of Science ®Google Scholar
• Tiang JM, Butcher NJ, Minchin RF. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2010;393:95–100.
   PubMed Web of Science ®Google Scholar
• Tiang JM, Butcher NJ, Minchin RF. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med. 2015;4:565–574.
   PubMed Web of Science ®Google Scholar
• Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49:361–374.
   PubMed Web of Science ®Google Scholar
• Nieman MT, Prudoff RS, Johnson KR, et al. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147:631–643.
   PubMed Web of Science ®Google Scholar
• Azimi I, Monteith GR. Plasma membrane ion channels and epithelial to mesenchymal transition in cancer cells. Endocr Relat Cancer. 2016;23:R517–R25.
   PubMed Web of Science ®Google Scholar
• Li P, Butcher NJ, Minchin R. Arylamine N-acetyltransferase 1 regulates expression of matrix metalloproteinase 9 in cancer cells: role of HIF1-alpha. Mol Pharmacol. 2019;96:573–579.
   PubMed Web of Science ®Google Scholar
• Hegedus L, Cho H, Xie X, et al. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol. 2008;216:480–485.
   PubMed Web of Science ®Google Scholar
• Nazir SU, Kumar R, Singh A, et al. Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor. Gene. 2019;711:143952.
   PubMed Web of Science ®Google Scholar
• Poincloux R, Collin O, Lizarraga F, et al. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc Natl Acad Sci U S A. 2011;108:1943–1948.
   PubMed Web of Science ®Google Scholar
• Steele JG, Dalton BA, Underwood PA, et al. Differences in adhesion to tissue culture plastic of clonally related transformed and control sublines from an epithelial cell strain. J Cell Sci. 1991;100(Pt 1):195–203.
   PubMedGoogle Scholar
• Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24.
   PubMed Web of Science ®Google Scholar
• Davis GE, Allen KAP, Salazar R, et al. Matrix metalloproteinase-1 and −9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001;114:917–930.
   PubMed Web of Science ®Google Scholar
• Juncker-Jensen A, Lund LR. Phenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice. Plos One. 2011;6:e16954.
   PubMed Web of Science ®Google Scholar
• Hill BS, Sarnella A, Capasso D, et al. Therapeutic potential of a novel α(v)β₃ antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. Cancers (Basel). 2019;11:139.
   PubMed Web of Science ®Google Scholar
• Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC. Therapeutic potential of matrix metalloproteinase inhibition in breast cancer. J Cell Biochem. 2017;118:3531–3548.
   PubMed Web of Science ®Google Scholar
• Winer A, Adams S, Mignatti P. matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17:1147–1155.
   PubMed Web of Science ®Google Scholar
• Mierke CT, Frey B, Fellner M, et al. Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci. 2011;124:369–383.
   PubMed Web of Science ®Google Scholar
• Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol. 2009;185:11–19.
   PubMed Web of Science ®Google Scholar
• Tachtsidis A, McInnes LM, Jacobsen N, et al. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastas. 2016;33:521–550.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687.
   PubMed Web of Science ®Google Scholar
• Brancaccio M, Hirsch E, Notte A, et al. Integrin signalling: the tug-of-war in heart hypertrophy. Cardiovasc Res. 2006;70:422–433.
   PubMed Web of Science ®Google Scholar
• Waisberg J, De Souza Viana L, Affonso Junior RJ, et al. Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. Anticancer Res. 2014;34:5599–5607.
   PubMed Web of Science ®Google Scholar
• Chen Q, Manning CD, Millar H, et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2008;25:139–148.
   PubMed Web of Science ®Google Scholar
• Li Y, Drabsch Y, Pujuguet P, et al. Genetic depletion and pharmacological targeting of alphav integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Res. 2015;17:28.
   PubMed Web of Science ®Google Scholar
• Schwickert A, Weghake E, Bruggemann K, et al. microRNA miR-142-3p inhibits breast cancer cell invasiveness by synchronous targeting of WASL, integrin alpha V, and additional cytoskeletal elements. PLoS One. 2015;10:e0143993.
   PubMed Web of Science ®Google Scholar
• Ma G, Jing C, Li L, et al. MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell carcinoma. Oncotarget. 2016;7:20209–20222.
   PubMedGoogle Scholar
• O’Day SJ, Pavlick AC, Albertini MR, et al. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs. 2012;30:1074–1081.
   PubMed Web of Science ®Google Scholar
• Cirkel GA, Kerklaan BM, Vanhoutte F, et al. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Invest New Drugs. 2016;34:184–192.
   PubMed Web of Science ®Google Scholar
• Ley K, Rivera-Nieves J, Sandborn WJ, et al. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016;15:173–183.
   PubMed Web of Science ®Google Scholar
• Wang L, Minchin RF, Butcher NJ. Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: role in the regulation of p53 stability. PLoS One. 2018;13:e0193560.
   PubMed Web of Science ®Google Scholar
• Butcher NJ, Ilett KF, Minchin RF. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000;57:468–473.
   PubMed Web of Science ®Google Scholar